Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 2 Mar 2017 |
| Orion Corporation: Transfer of 107,965 own B-shares on 1 March 2017 | 1 Mar 2017 |
| Orion Group Financial Statement documents 2016 and Corporate Governance Statement published | 27 Feb 2017 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 21 Feb 2017 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 16 Feb 2017 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 15 Feb 2017 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 15 Feb 2017 |